NEJM:艾滋病患者接受ART后10年生存率能达七成

2016-02-01 MedSci MedSci原创

我们报道了一项关于艾滋病患者接受连续抗逆转录病毒治疗(ART)后10年生存率的队列研究,该研究来自海地太子港,纳入自2003至2004年间入院接受ART、且年龄大等于13岁的患者共910例,随访时间为10年;ART与随访期间护理均严格按照世界卫生组织(WHO)指南。该回顾性队列研究的有关细节已有报道,已获得有关机构审查委员会伦理学批准。死亡事件可从医疗记录中确定。转院患者资料在转院时审查。将随访终

一项来自海地太子港关于艾滋病患者接受连续抗逆转录病毒治疗(ART)后10年生存率的队列研究,该研究纳入自2003至2004年间入院接受ART、且年龄大等于13岁的患者共910例,随访时间为10年;ART与随访期间护理均严格按照世界卫生组织(WHO)指南。

该回顾性队列研究的有关细节已有报道(包括研究人群,以及5年的生存率,见附参考文献),已获得有关机构审查委员会伦理学批准。死亡事件可从医疗记录中确定。转院患者资料在转院时审查。将随访终点前超过180天无临床接触定义为失访。


研究采用以下三种方法评估失访患者生存状态并估计10年生存率:Kaplan-Meier法审查失访时患者数据,逆概率加权法用于追踪数据,多重插补法可基于基线特征评估失访患者生存率。利用Cox模型确定10年生存相关特性。基线入组的910例患者中,女504例(55%),年龄中位数为39岁,CD4+T细胞计数中位数为131/mm3(四分位距为51-212)。近半数患者极度贫困,每日收入不足1美元。

入组患者接受ART方案10年后,存活482例(53%),死亡246例(27%),失访111例(12%),转院71例(8%)。

通过Kaplan-Meier法、逆概率加权法( inverse-probability weighting)、多重插补法(multiple imputation )估算的10年生存率相似,分别为: 71%(95% CI,68~74)、63%(95% CI,59~67)、67%(95% CI,64~71)。

死亡患者中,42%死亡时间为接受治疗后6个月内;该期间患者死亡与男性、年龄大于50岁、体重在相应性别最低四分位数、合并WHO定义的III或IV期疾病、伴有活动性肺结核等因素相关(P<0.05)。6个月后死亡的危险因素包括:年龄大于 50岁、每日收入不足1美元、体重处于最低四分位数、治疗依从性处于最低四分位数等(P<0.05)。尽管2010年发生地震,该年死亡率与其它年份相比并无显著差异。

482例存活患者中,351例(73%)继续接受一线治疗,178例(37%)患有慢性非传染性疾病(其中心血管疾病109例、肺部疾病67例、糖尿病2例)。

在发展中国家,绝大部分患者接受ART时处于艾滋病晚期。该研究为首批关于发展中国家患者接受ART的大型队列研究之一,估算10年生存率为63%-71%,与美国接受ART的艾滋病早期患者生存率相似。研究结果表明,为资源匮乏的国家患者提供ART有赖于长期、可持续的国际合作。

原始出处:

Pierre S, Pape J, McNairy ML, Jannat-Khah D, Fitzgerald DW.10-Year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti. N Engl J Med. 2016 Jan 28;374(4):397-8.

Severe PLeger PCharles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med2005;353:2325-2334 Free Full Text 

Leger PCharles MSevere PRiviere C,Pape JWFitzgerald DW. 5-Year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med 2009;361:828-829 Free Full Text

ART治疗

鸡尾酒疗法,原指“高效抗逆转录病毒治疗”(HAART),由美籍华裔科学家何大一于1996年提出,是通过三种或三种以上的抗病毒药物联合使用来治疗艾滋病。该疗法的应用可以减少单一用药产生的抗药性,最大限度地抑制病毒的复制,使被破坏的机体免疫功能部分甚至全部恢复,从而延缓病程进展,延长患者生命,提高生活质量。该疗法把蛋白酶抑制剂与多种抗病毒的药物混合使用,从而使艾滋病得到有效的控制。

越来越多的科学家相信,混合药物疗法是对付艾滋病的最有效治疗方法,既可以阻止艾滋病病毒繁殖,又可以防止体内产生抗药性的病毒。近年来在其他疾病上,也有人将类似的联合用药疗法称为相对应的“鸡尾酒疗法”。

MedSci提示:

Kaplan-Meier法审查失访时患者数据,逆概率加权法用于追踪数据,多重插补法可基于基线特征评估失访患者生存率,这三种统计策略都进行了应用,也是常见的三种方法,你懂了吗?如果不了解这些,可以向MedSci提供相关服务哦

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958053, encodeId=d2c6195805335, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Oct 23 18:32:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63823, encodeId=854c63823a5, content=有些哪, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 21:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256529, encodeId=615212565294f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356050, encodeId=3c701356050ca, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62666, encodeId=db9f6266628, content=希望有新的突跛, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 23:04:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62663, encodeId=cb57626630f, content=希望能有进一步进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:52:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62508, encodeId=774c625089e, content=抗艾!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62509, encodeId=cce76250979, content=加油必胜, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958053, encodeId=d2c6195805335, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Oct 23 18:32:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63823, encodeId=854c63823a5, content=有些哪, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 21:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256529, encodeId=615212565294f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356050, encodeId=3c701356050ca, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62666, encodeId=db9f6266628, content=希望有新的突跛, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 23:04:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62663, encodeId=cb57626630f, content=希望能有进一步进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:52:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62508, encodeId=774c625089e, content=抗艾!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62509, encodeId=cce76250979, content=加油必胜, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-09 忠诚向上

    有些哪

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1958053, encodeId=d2c6195805335, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Oct 23 18:32:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63823, encodeId=854c63823a5, content=有些哪, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 21:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256529, encodeId=615212565294f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356050, encodeId=3c701356050ca, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62666, encodeId=db9f6266628, content=希望有新的突跛, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 23:04:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62663, encodeId=cb57626630f, content=希望能有进一步进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:52:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62508, encodeId=774c625089e, content=抗艾!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62509, encodeId=cce76250979, content=加油必胜, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958053, encodeId=d2c6195805335, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Oct 23 18:32:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63823, encodeId=854c63823a5, content=有些哪, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 21:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256529, encodeId=615212565294f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356050, encodeId=3c701356050ca, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62666, encodeId=db9f6266628, content=希望有新的突跛, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 23:04:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62663, encodeId=cb57626630f, content=希望能有进一步进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:52:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62508, encodeId=774c625089e, content=抗艾!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62509, encodeId=cce76250979, content=加油必胜, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-03 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958053, encodeId=d2c6195805335, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Oct 23 18:32:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63823, encodeId=854c63823a5, content=有些哪, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 21:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256529, encodeId=615212565294f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356050, encodeId=3c701356050ca, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62666, encodeId=db9f6266628, content=希望有新的突跛, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 23:04:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62663, encodeId=cb57626630f, content=希望能有进一步进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:52:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62508, encodeId=774c625089e, content=抗艾!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62509, encodeId=cce76250979, content=加油必胜, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-01 dhzzm

    希望有新的突跛

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1958053, encodeId=d2c6195805335, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Oct 23 18:32:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63823, encodeId=854c63823a5, content=有些哪, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 21:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256529, encodeId=615212565294f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356050, encodeId=3c701356050ca, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62666, encodeId=db9f6266628, content=希望有新的突跛, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 23:04:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62663, encodeId=cb57626630f, content=希望能有进一步进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:52:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62508, encodeId=774c625089e, content=抗艾!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62509, encodeId=cce76250979, content=加油必胜, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-01 vinson820801

    希望能有进一步进展

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1958053, encodeId=d2c6195805335, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Oct 23 18:32:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63823, encodeId=854c63823a5, content=有些哪, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 21:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256529, encodeId=615212565294f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356050, encodeId=3c701356050ca, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62666, encodeId=db9f6266628, content=希望有新的突跛, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 23:04:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62663, encodeId=cb57626630f, content=希望能有进一步进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:52:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62508, encodeId=774c625089e, content=抗艾!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62509, encodeId=cce76250979, content=加油必胜, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-01 李继凯

    抗艾!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1958053, encodeId=d2c6195805335, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Oct 23 18:32:00 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63823, encodeId=854c63823a5, content=有些哪, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 21:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256529, encodeId=615212565294f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356050, encodeId=3c701356050ca, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 03 00:32:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62666, encodeId=db9f6266628, content=希望有新的突跛, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Mon Feb 01 23:04:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62663, encodeId=cb57626630f, content=希望能有进一步进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5b91683812, createdName=vinson820801, createdTime=Mon Feb 01 22:52:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62508, encodeId=774c625089e, content=抗艾!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62509, encodeId=cce76250979, content=加油必胜, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Mon Feb 01 15:27:00 CST 2016, time=2016-02-01, status=1, ipAttribution=)]
    2016-02-01 李继凯

    加油必胜

    0

相关资讯

世界艾滋病日:带来治愈希望的新技术

为提高人们对艾滋病的认识,世界卫生组织于1988年将每年的12月1日定为世界艾滋病日,号召世界各国和国际组织在这一天举办相关活动,宣传和普及预防艾滋病的知识。从2011年开始,世界艾滋病日的主题都一直是Getting to Zero——零感染,零歧视和零死亡。而今年,联合国会员国也提出了更新应对艾滋病的目标,即在2030年前结束艾滋病流行。 这也就是说“结束艾滋病”已经被提上了日程,虽然我们身

近5年我国大中学生艾滋病病毒感染者年增35%

今天,中国疾控中心性病艾滋病防治中心主任吴尊友透露,2014年,全国15至24岁新增报告艾滋病人数为1.5万多人。今年1到10月,该年龄段有1.4万多人感染艾滋病病毒。与去年同期相比,今年感染的青少年人数比去年增长了10%左右。他担忧地说:“青少年受到艾滋病病毒的威胁越来越大。”“2011年到2015年,我国15~24岁大中学生艾滋病病毒感染者净年均增长率达35%(扣除检测增加的因素)。”按照吴尊

世卫组织:关于艾滋病/HIV的实况报道

重要事实HIV依然是威胁全球人类健康的一大问题,到目前为止HIV已剥夺了3400多万人的性命。2014年,全球范围内HIV相关原因所致的死亡人数达120万。至2014年底,全球的HIV病毒感染者将近有3690万;2014年,全球范围内HIV新感染患者达200万。撒哈拉以南非洲是HIV感染最严重的地区,2014年该地区有2580万HIV病毒感染者;此外,全球所有的HIV新感染患者,有将近70%来

2015年关于HIV/AIDS的10大事实

尽管目前对HIV/AIDS的认识等有重大进展,但是HIV/AIDS依旧是全球范围内重大公共卫生挑战,尤其是低中收入国家;撒哈拉以南非洲女性风险尤其高。自1984年起,每年的12月1日作为世界艾滋病日,这一天将举办各种宣传和普及预防艾滋病的知识有关活动,意在团结大众抵抗HIV,支持HIV感染人群,纪念已故人群。9月联合国成员达成一致协议:将于2030年终结AIDS的流行。虽然目标宏伟,但根据WHO、

为什么艾滋病毒总在花季少年中肆虐?

在2015年世界艾滋病日到来前夕,由淡蓝公益、Blued、中国好声音主办的“青春零艾滋”世界艾滋病日活动在京举办。活动以青年+社区为目标群体,希望通过宣传活动将艾滋病防治工作直达易感人群。近年来,艾滋病感染群体中的青年感染者比例骤然上升,数据显示,2011年—2015年10月份,青年学生感染艾滋病的平均涨幅上升到了49%。是什么原因让艾滋病毒在这群花季少年中肆虐?如何对这些青年学生进行教育就显得迫

疾控中心:艾滋病常见问题解答

艾滋病毒是如何传播的?艾滋病毒可通过与感染者发生未保护的性交(阴道交或肛交)和口交;输入受艾滋病毒污染的血液;共用受艾滋病毒污染的针头、针具或其他锐器等途径传播。还可通过受艾滋病毒感染的母亲在妊娠、分娩和哺乳期间传播给婴儿。艾滋病毒感染者多长时间发展为艾滋病患者?由艾滋病毒感染者发展为艾滋病患者的时间存在很大的个体差异。如果没有获得相应的治疗,大部分艾滋病毒感染者在感染后5-10年内出现艾滋病毒相